Key facts
- It has raised $30K; the latest was Seed Round ($30K) in Apr 2025.
- Notable investors include TEDCO.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Neuros Biotechnology
- ·The full record, as it builds
Funding rounds
No funding rounds for Neuros Biotechnology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Neuros Biotechnology
Operator of a neurogenic therapy intended to holistically treat and reverse alzheimer's disease by targeting neuroplastic deficiency and cognitive decline. The company offers a regenerative, human-derived mixed biologic with unique neuro-restorative properties, enabling individuals with alzheimer's and mild cognitive impairment to regain cognitive function and prevent further disease progression.
- Sector
- Healthcare
- HQ
- Sunderland, MD, United States
- Founded
- 2020
- Employees
- 4
- Website
- neurosbio.com/
- Ownership
- Privately Held (backing)
Neuros Biotechnology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Neuros Biotechnology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Neuros Biotechnology in its N-PORT filings yet. We sweep new filings monthly.